SUGAR LAND--August 3, 2010--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Like many courtships, French drug giant Sanofi-Aventis' (NYSE:SNY) (U.S. Headquarters: Bridgewater, New Jersey) interest in biological manufacturer Genzyme (NASDAQ:GENZ) (Cambridge, Massachusetts) began with, and remains mired in, rumors. Through the month of July, hints of Sanofi's interest in acquiring the troubled biotech filtered out, thanks to a series of "anonymous" press leaks. By close of business Friday, July 30, 2010, the expected formal announcement of a $19 billion Sanofi offer for Genzyme never happened.